[PDF][PDF] 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the …

…, SL Bridges Jr, WW Chatham… - Arthritis care & …, 2012 - Wiley Online Library
Chatham has served as a paid consultant with investment analysts on behalf of Gerson
Lehrman and Leerink-Swann. Dr. Bombardier has received honoraria (less than $10,000 each) …

Treatment of lupus with corticosteroids

WW Chatham, RP Kimberly - Lupus, 2001 - journals.sagepub.com
Through direct signals to the nucleus mediated by the glucocorticoid receptor, exogenous
glucocorticoids impact a broad array of cellular functions. DNA binding of the glucocorticoid …

Cytokine storm syndrome

RQ Cron, G Goyal, WW Chatham - Annual Review of Medicine, 2023 - annualreviews.org
Cytokine storm syndrome (CSS), which is frequently fatal, has garnered increased attention
with the ongoing coronavirus pandemic. A variety of hyperinflammatory conditions …

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis

…, SL Bridges Jr, WW Chatham… - Arthritis Care & …, 2008 - Wiley Online Library
Chatham has received speaking fees and honoraria (less than $10,000 each) from Bristol-Myers
Squibb and Amgen. Dr. Hochberg has received consultant fees (less than $10,000 …

A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus …

…, A Schwarting, JT Merrill, WW Chatham… - Arthritis & …, 2011 - Wiley Online Library
Chatham has received research or grant support and travel support from Human Genome
Chatham has received research or grant support and travel support from Human Genome …

Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III …

B Shakoory, JA Carcillo, WW Chatham… - Critical care …, 2016 - journals.lww.com
Chatham’s institution received grant support from Swedish Orphan Biovitrum (SOBI) (pending
grant for clinical trial re: anakinra in MAS). Dr. Cron provided expert testimony for Wicker …

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus

…, MA Petri, EM Ginzler, WW Chatham… - Arthritis Care & …, 2009 - Wiley Online Library
Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …

Novel evidence‐based systemic lupus erythematosus responder index

…, JT Merrill, W Stohl, WW Chatham… - Arthritis Care & …, 2009 - Wiley Online Library
Objective To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based
on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials…

Drs. Cron and Chatham reply

RQ Cron, WW Chatham - The Journal of rheumatology, 2020 - jrheum.org
We value Dr. Caricchio’s and Dr. Criner’s appreciation of our commentary on the role of
rheumatologists in the coronavirus disease 2019 (COVID-19) pandemic1. We applaud Temple …

[HTML][HTML] Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity

…, S Hall, BA Julian, WW Chatham… - The Journal of …, 2009 - Am Soc Clin Investig
IgA nephropathy (IgAN) is characterized by circulating immune complexes composed of
galactose-deficient IgA1 and a glycan-specific IgG antibody. These immune complexes deposit …